MDXG at a glance
MIMEDX GROUP, INC. (MDXG, SEC CIK 1376339) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on July 29, 2026, an 8-K current report on August 11, 2026 and Form 4 insider filings as recently as July 7, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), MIMEDX GROUP, INC. (MDXG) reported revenue of $418.6 million (up 20.0% from FY2024) and net income of $48.6 million. Diluted EPS was $0.32.
- As of June 30, 2026, 31 institutional investment managers tracked by SignalX reported holding MIMEDX GROUP, INC. (MDXG) shares worth $154.5 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $418.6M
- +20.0% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 31 funds
- $154.5M · +1 vs prior quarter
- Latest 8-K
- Aug 11, 2026
- Item 7.01 · Item 1.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Q2 revenue $64.4M, down 34.7% YoY from $98.6M
- Gross margin 69.0% vs 81.1% YoY; GAAP net loss $14.8M vs $9.6M income
- Best segment Surgical revenue $39.3M, up 15.1%; worst Wound revenue $25.1M, down 61.1%
- Cash $135.8M; six-month operating cash flow $(8.1)M vs $19.7M; Q2 repurchases $12.5M
- Medicare reimbursement changes, credit deterioration, and cost-reduction severance remained near-term headwinds; liquidity expected for twelve months
Risk Factors
- No material changes from the 2025 Form 10-K risk factors
- No newly triggered risk factor disclosed in the quarter
- No regulatory, legal, compliance, operational, competitive, market, or financial risk updates provided
AI summary of the MDXG 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Proposed MiMedx–Sanara merger remains subject to regulatory filings, shareholder approval and closing conditions
- Management highlights potential combined surgical revenue and Adjusted EBITDA margin benefits, without quantified estimates here
Item 1.01: Entry into a Material Definitive Agreement
- MiMedx to acquire Sanara for $33.00 cash plus 0.4735 MiMedx shares per Sanara share, implying $35.00 total stated consideration
- $300.0 million first-lien senior secured term loan planned, increasing leverage and replacing MiMedx’s existing credit facility
Item 2.02: Results of Operations and Financial Condition
- Filing provides no earnings figures; text only addresses incorporation-by-reference and update disclaimers
- Investor-relevant operating results require review of the referenced Earnings Press Release
Item 7.01: Regulation FD Disclosure
- Conference call scheduled July 29, 2026, at 4:30 PM EDT for first-quarter 2026 financial and operating results
- Exhibit 99.2 contains earnings-call slides, providing investors management’s planned results narrative
Item 7.01: Regulation FD Disclosure
- Proposed MiMedx–Sanara merger remains subject to stockholder approval, regulatory clearances, financing, and other closing conditions
- Management highlights potential combined surgical revenue and Adjusted EBITDA margin benefits, without quantified figures here
Item 1.01: Entry into a Material Definitive Agreement
- MiMedx to acquire Sanara for $33.00 cash plus 0.4735 MiMedx shares per Sanara share, implying $35.00 total stated consideration
- $300.0 million first-lien senior secured term loan financing, increasing leverage and replacing MiMedx’s existing credit facility
AI summaries of MDXG 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for MDXG
Don't miss the next MDXG filing
- Alerts as it files. A push when MDXG files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut MDXG, by share count.
- Ask anything. An AI agent that reads every MDXG filing and answers with sources.
MDXG alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| DOUG RICE | F | Jul 2, 2026 | 12,749 | $3.95 |
| Maersk-Moller Kimberly | F | Jun 24, 2026 | 19,820 | $3.83 |
| PUHY DOROTHY E | A | Jun 10, 2026 | 50,913 | $3.64 |
| HAWKINS WILLIAM A | A | Jun 10, 2026 | 50,913 | $3.64 |
| Olson Tiffany | A | Jun 10, 2026 | 50,913 | $3.64 |
| BIERMAN JAMES L | A | Jun 10, 2026 | 50,913 | $3.64 |
| Newton Todd | A | Jun 10, 2026 | 50,913 | $3.64 |
| Maersk-Moller Kimberly | F | Mar 13, 2026 | 6,762 | $4.38 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $348.9M | $418.6M |
| Gross Profit | - | $288.8M | $345.6M |
| Operating Income | $37.1M | $58.9M | $63.9M |
| Net Income | $58.2M | $42.4M | $48.6M |
| Gross Margin | - | 82.8% | 82.6% |
| Op. Margin | - | 16.9% | 15.3% |
| Net Margin | - | 12.2% | 11.6% |
| Balance Sheet | |||
| Total Assets | $239.0M | $263.9M | $342.7M |
| Equity | - | $193.1M | $256.5M |
| ROE | - | 22.0% | 18.9% |
| Per Share | |||
| EPS | - | $0.28 | $0.32 |
| Cash Flow | |||
| Operating CF | - | $66.2M | $74.0M |
| CapEx | $2.0M | - | - |
Source: XBRL data in MIMEDX GROUP, INC. (MDXG)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate MDXG share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 31 | $154.5M |
| Q1 2026 | 30 | $146.2M |
| Q4 2025 | 28 | $238.8M |
| Q3 2025 | 30 | $253.7M |
| Q2 2025 | 30 | $221.8M |
| Q1 2025 | 28 | $176.6M |
| Q4 2024 | 23 | $177.9M |
| Q3 2024 | 19 | $69.4M |
- AQR Capital Management+1.55M (+170%)
- Goldman Sachs Group+1.48M (+125%)
- State Street Corp+522.1K (+10%)
- Northern Trust+294.5K (+29%)
- BlackRock+243.2K (+2%)
- Dimensional Fund Advisors−749.1K (-28%)
- Prudential Financial−623.6K (-93%)
- Renaissance Technologies LLC−575.6K (-19%)
- Two Sigma Investments−20.7K (-8%)
- T. Rowe Price Group−18.5K (-16%)
- Allstate+75.2K
- U.S. Bancorp+60
- Millennium Management−200.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 219 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
MDXG filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| 10-Q | Jul 29, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| 4 | Jul 7, 2026 | - | - | - |
| 4 | Jun 25, 2026 | - | - | - |
| 8-K | Jun 16, 2026 | - | Analysis | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 10-Q | Apr 29, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 29, 2026 | - | Analysis | - |
| 8-K | Apr 16, 2026 | - | Analysis | - |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 12, 2026 | - | - | - |
| 4 | Mar 12, 2026 | - | - | - |
| 4 | Mar 12, 2026 | - | - | - |
| 4 | Mar 6, 2026 | - | - | - |
| 4 | Mar 6, 2026 | - | - | - |
| 4 | Mar 6, 2026 | - | - | - |
| 4 | Mar 6, 2026 | - | - | - |
| 4 | Mar 6, 2026 | - | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
MDXG SEC filings: frequently asked questions
Which institutions hold MDXG stock?
As of June 30, 2026, the largest MIMEDX GROUP, INC. (MDXG) holders among the 13F filers tracked by SignalX were BlackRock ($46.8 million), State Street Corp ($21.5 million), Vanguard Capital Management LLC ($20.0 million), Goldman Sachs Group ($10.3 million), AQR Capital Management ($9.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was MDXG's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), MIMEDX GROUP, INC. (MDXG) reported revenue of $418.6 million (up 20.0% from FY2024) and net income of $48.6 million. Diluted EPS was $0.32. The figures come from the XBRL data in the 10-K.
What did MDXG report in its latest 8-K?
MIMEDX GROUP, INC. (MDXG) filed an 8-K on August 11, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 1.01 (Entry into a Material Definitive Agreement). Proposed MiMedx–Sanara merger remains subject to regulatory filings, shareholder approval and closing conditions.
What are the latest MDXG SEC filings?
MIMEDX GROUP, INC. (MDXG) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on July 29, 2026, an 8-K current report on August 11, 2026 and a Form 4 insider filing on July 7, 2026.
What is MDXG's SEC CIK number?
MIMEDX GROUP, INC. (MDXG)'s SEC Central Index Key (CIK) is 1376339. EDGAR lists every MDXG filing under that number.
Ask anything about MDXG
The research agent reads MDXG's filings, financials, insider trades and 13F holders, then answers with sources.